• Company
• Domestic market withdrawal of Forxiga remains a mystery
• by Kim, Jin-Gu Dec 14, 2023 05:47am

• Company
• Rinvoq is granted reimb for ankylosing spondylitis
• by Son, Hyung-Min Dec 14, 2023 05:47am

• Company
• Reimb of latecomer leukemia drug Bosulif imminent
• by Eo, Yun-Ho Dec 14, 2023 05:47am

• Policy
• Will Enhertu be reimbursed using flexible ICER threshold?
• by Lee, Tak-Sun Dec 14, 2023 05:47am

• Company
• Daewoong attempts at first Lupron Depot generic in the US
• by Chon, Seung-Hyun Dec 13, 2023 05:38am

• Policy
• Only CKD and Jeil have high-dose Xeljanz generics approved
• by Lee, Hye-Kyung Dec 13, 2023 05:38am

• Opinion
• [Reporter’s View] Amid hopes for K-drugs, beware
• by Eo, Yun-Ho Dec 13, 2023 05:38am

• Company
• Jeil will exclusively supply Norvatis’ 9 ophthalmic drugs
• by Nho, Byung Chul Dec 12, 2023 10:33pm

• Company
• Evenity and Prolia sales surge...combined sales rise 47%
• by Kim, Jin-Gu Dec 12, 2023 05:38am

• Policy
• KIDS ‘Oral VEGFR-TKI use may increase risk of AAD’
• by Lee, Hye-Kyung Dec 12, 2023 05:38am